Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.


Munir, Talha, Cairns, David A, Bloor, Adrian, Allsup, David, Cwynarski, Kate, Pettitt, Andrew ORCID: 0000-0002-0907-8950, Paneesha, Shankara, Fox, Christopher P, Eyre, Toby A, Forconi, Francesco ORCID: 0000-0002-2211-1831 et al (show 23 more authors) (2024) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. The New England journal of medicine, 390 (4). pp. 326-337.

[img] Text
23-10063.R2_Proof_hi.pdf - Author Accepted Manuscript
Available under License Creative Commons Attribution No Derivatives.
Download (435kB) | Preview
[img] Text
FCR vs IV Appendix-v3.0.pdf - Supporting information
Download (1MB) | Preview

Abstract

<h4>Background</h4>The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration according to measurable residual disease (MRD) is more effective than fludarabine-cyclophosphamide-rituximab (FCR) is unclear.<h4>Methods</h4>In this phase 3, multicenter, randomized, controlled, open-label platform trial involving patients with untreated CLL, we compared ibrutinib-venetoclax and ibrutinib monotherapy with FCR. In the ibrutinib-venetoclax group, after 2 months of ibrutinib, venetoclax was added for up to 6 years of therapy. The duration of ibrutinib-venetoclax therapy was defined by MRD assessed in peripheral blood and bone marrow and was double the time taken to achieve undetectable MRD. The primary end point was progression-free survival in the ibrutinib-venetoclax group as compared with the FCR group, results that are reported here. Key secondary end points were overall survival, response, MRD, and safety.<h4>Results</h4>A total of 523 patients were randomly assigned to the ibrutinib-venetoclax group or the FCR group. At a median of 43.7 months, disease progression or death had occurred in 12 patients in the ibrutinib-venetoclax group and 75 patients in the FCR group (hazard ratio, 0.13; 95% confidence interval [CI], 0.07 to 0.24; P<0.001). Death occurred in 9 patients in the ibrutinib-venetoclax group and 25 patients in the FCR group (hazard ratio, 0.31; 95% CI, 0.15 to 0.67). At 3 years, 58.0% of the patients in the ibrutinib-venetoclax group had stopped therapy owing to undetectable MRD. After 5 years of ibrutinib-venetoclax therapy, 65.9% of the patients had undetectable MRD in the bone marrow and 92.7% had undetectable MRD in the peripheral blood. The risk of infection was similar in the ibrutinib-venetoclax group and the FCR group. The percentage of patients with cardiac serious adverse events was higher in the ibrutinib-venetoclax group than in the FCR group (10.7% vs. 0.4%).<h4>Conclusions</h4>MRD-directed ibrutinib-venetoclax improved progression-free survival as compared with FCR, and results for overall survival also favored ibrutinib-venetoclax. (Funded by Cancer Research UK and others; FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.).

Item Type: Article
Uncontrolled Keywords: National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup, Humans, Neoplasm, Residual, Sulfonamides, Cyclophosphamide, Vidarabine, Antineoplastic Combined Chemotherapy Protocols, Time Factors, Leukemia, Lymphocytic, Chronic, B-Cell, Rituximab, Bridged Bicyclo Compounds, Heterocyclic, Duration of Therapy
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 09 Jan 2024 11:27
Last Modified: 02 Feb 2024 15:56
DOI: 10.1056/nejmoa2310063
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3177737
Dimensions
Altmetric
CORE (COnnecting REpositories)